Tocilizumab resistance management

Tocilizumab is an injectable formulation that can be used alone or in combination with other medications to relieve the symptoms of certain types of arthritis and other diseases, including those who are not receiving other disease-modifying antirheumatic drugs< DMARDs are used to treat rheumatoid arthritis, adult giant cell arteritis, systemic sclerosis-related interstitial lung disease, and cytokine release syndrome. They are also used to treat polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis in children 2 years of age or older.

Using tocilizumab may reduce your ability to fight bacterial, viral, and fungal infections and increase your risk of serious or life-threatening infections that may spread throughout your body. No serious adverse drug reactions were observed in healthy volunteers receiving single doses up to 28 mg/kg, although patients developed dose-limiting neutropenia at the highest dose of 28 mg/kg. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

TocilizumabThe original drug has been launched in China and has been included in the medical insurance. Due to its short time on the market, the second-line treatment of systemic juvenile idiopathic arthritis is still limited to traditional treatments for rheumatoid arthritisDMARDs To treat patients whose disease activity has decreased by less than 50% in 3 to 6 months, Tocilizumab injection can only be used as directed by the doctor. Its price is around RMB 8,600, which is relatively expensive. The price of the European version of tocilizumab original drug available overseas is around around RMB 14,000 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of the two drugs are basically the same. Currently, there are no generic drugs produced and marketed overseas, and patients can choose by themselves.